IGF-1 splice-associated research peptide · Fact sheet
Mechano-growth factor
Also known as MGF · IGF-1 Ec E-domain peptide
Mechano-growth factor is a name used for an IGF-1 splice-related precursor and for a proposed E-domain peptide. Evidence for the isolated peptide is disputed and does not establish human muscle repair.
What is Mechano-growth factor?
IGF-1 splice variants and an isolated synthetic E-domain peptide are different research objects. Papers using the same MGF name may not test the same substance.
This entry focuses on the isolated peptide rather than all expression of the IGF-1 gene.
Benefits & claims
Exercise-associated gene expression led to interest in local muscle regeneration. Increased expression after injury is not proof that administering an isolated peptide is beneficial.
What the evidence supports
- The replication study observed responses to mature IGF-1 and full-length IGF-1Eb, but not to the isolated MGF peptides tested.
- Other work explores periodontal or cardiac mechanisms rather than demonstrating human muscle recovery.
- The biological identity and reproducibility problems should be resolved before claiming a treatment benefit.
Research areas
- Muscle-cell proliferation
- IGF-1 splice biology
- Preclinical tissue repair
Dosage & frequency
No established human regimenThe reviewed sources do not establish a human treatment amount or frequency for Mechano-growth factor. Animal and laboratory exposures are not human regimens.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- IGF-1 splice variants and an isolated synthetic E-domain peptide are different research objects. Papers using the same MGF name may not test the same substance.
Formulation differences
- This entry focuses on the isolated peptide rather than all expression of the IGF-1 gene.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Reproducible activity of chemically defined MGF peptide
- Human safety and functional outcomes
- Relationship between precursor expression and administered peptide
Side effects & risks
- Human safety and immunogenicity of the isolated peptide are inadequately characterized.
- Confusing endogenous gene expression with an administered research product can obscure which substance was actually tested.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Mostly animal or lab researchA direct replication study found no apparent proliferative or differentiation effect of MGF peptides in human and mouse muscle cells. Other preclinical findings use different models and formulations.
Studies
No apparent effect of isolated peptides on myoblasts or primary muscle stem cells.
C2C12 cell study of expression and transformation.
Preclinical mechanochemical investigation; not a human recovery regimen.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
No FDA-approved MGF therapeutic product is established. Laboratory work on splice variants does not document an approved recovery treatment.
Preclinical evidence; no FDA-approved product
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Reproducible activity of chemically defined MGF peptide
- Human safety and functional outcomes
- Relationship between precursor expression and administered peptide
Summary
The biological identity and reproducibility problems should be resolved before claiming a treatment benefit.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedMGF replication study
No apparent effect of isolated peptides on myoblasts or primary muscle stem cells.
- pubmedMGF and periodontal regeneration
Preclinical mechanochemical investigation; not a human recovery regimen.